Results 21 to 30 of about 326,057 (302)

Nilotinib-Associated Destructive Thyroiditis

Case Reports in Endocrinology, 2015
Protein tyrosine kinase inhibitors are currently an important drug class in the treatment of leukemia. They represent targeted cancer therapy and have become the treatment of choice in chronic myeloid leukemia.
Suhalia Bakerywala, Monica D. Schwarcz, Michael D. Goldberg, Guy Valiquette, Irene A. Weiss   +4 more
doaj   +1 more source

Outcome of 82 chronic myeloid leukemia patients treated with nilotinib or dasatinib after failure of two prior tyrosine kinase inhibitors

Haematologica, 2013
There have been few reports of a response to dasatinib or nilotinib after failure of two prior sequential tyrosine kinase inhibitors. We report the outcome of 82 chronic phase patients who received nilotinib or dasatinib as third-line alternative ...
Antonella Russo Rossi, Massimo Breccia, Elisabetta Abruzzese, Fausto Castagnetti, Luigiana Luciano, Antonella Gozzini, Mario Annunziata, Bruno Martino, Fabio Stagno, Francesco Cavazzini, Mario Tiribelli, Giuseppe Visani, Patrizia Pregno, Pellegrino Musto, Carmen Fava, Nicola Sgherza, Francesco Albano, Gianantonio Rosti, Giuliana Alimena, Giorgina Specchia   +19 more
doaj   +1 more source

Tyrosine kinase inhibitor Tofacitinib. Safety issues

Медицинский совет, 2015
Tofacitinib (TOFA) was the first synthetic small molecule drug which was comparable with genetically engineered biological agents (GIBA) in terms of its therapeutic effect in rheumatoid arthritis (RA).
G. V. Lukina, Y. A. Sigidin
doaj   +1 more source

Abcg2 overexpression represents a novel mechanism for acquired resistance to the multi-kinase inhibitor Danusertib in BCR-ABL-positive cells in vitro. [PDF]

, 2011
The success of Imatinib (IM) therapy in chronic myeloid leukemia (CML) is compromised by the development of IM resistance and by a limited IM effect on hematopoietic stem cells.
Carsten Bokemeyer, Balabanov, S., Moll, J., Tessa L. Holyoake, Edgar Jost, Braig, Melanie, Stefan Balabanov, Moll, Jürgen, Rohe, Imke, Gontarewicz, A., Gunhild Keller, von Amsberg, Gunhild, Braig, M., Holyoake, Tessa L., Jost, E., Rohe, I., Jost, Edgar, Bosotti, Roberta, Tim H Brümmendorf, Bosotti, R., Balabanov, Stefan, Barett, Christine, Artur Gontarewicz, Holyoake, T.L., Laura Raddrizzani, Brümmendorf, T.H., Gontarewicz, Artur, Roberta Bosotti, Barett, C., Raddrizzani, Laura, Melanie Braig, Raddrizzani, L., Bokemeyer, C., Jürgen Moll, Tessa L Holyoake, Keller, G., Tim H. Brümmendorf, Bokemeyer, Carsten, Brümmendorf, Tim Henrik, Imke Rohe, Christine Barett   +40 more
core   +1 more source

Dasatinib inhibits CXCR4 signaling in chronic lymphocytic leukaemia cells and impairs migration towards CXCL12 [PDF]

, 2012
Chemokines and their ligands play a critical role in enabling chronic lymphocytic leukaemia (CLL) cells access to protective microenvironmental niches within tissues, ultimately resulting in chemoresistance and relapse: disruption of these signaling ...
McCaig, Alison M., Alison M McCaig, Alison M. Mccaig, Cosimo Emilio, Alison M. Michie, Leach Michael T., Alison M Michie, Emilio Cosimo, Michael T. Leach, McCaig Alison M., Michael T Leach, Michie, Alison M., Michie Alison M., Cosimo, Emilio, Leach, Michael T.   +14 more
core   +1 more source

Anexelekto/MER tyrosine kinase inhibitor ONO-7475 arrests growth and kills FMS-like tyrosine kinase 3-internal tandem duplication mutant acute myeloid leukemia cells by diverse mechanisms

Haematologica, 2017
Nearly one-third of patients with acute myeloid leukemia have FMS-like tyrosine kinase 3 mutations and thus have poor survival prospects. Receptor tyrosine kinase anexelekto is critical for FMS-like tyrosine kinase 3 signaling and participates in FMS ...
Peter P. Ruvolo, Huaxian Ma, Vivian R. Ruvolo, Xiaorui Zhang, Hong Mu, Wendy Schober, Ivonne Hernandez, Miguel Gallardo, Joseph D. Khoury, Jorge Cortes, Michael Andreeff, Sean M. Post   +11 more
doaj   +1 more source

Lichen planopilaris-like eruption during treatment with tyrosine kinase inhibitor nilotinib [PDF]

Anais Brasileiros de Dermatologia, 2016
Tyrosine kinase inhibitors are effective as a target therapy for malignant neoplasms. Imatinib was the first tyrosine kinase inhibitor used. After its introduction, several other drugs have appeared with a similar mechanism of action, but less prone to ...
Juliana Ribeiro Leitão, Neusa Yuriko Sakai Valente, Priscila Kakizaki, Isis Suga Veronez, Mario Cezar Pires   +4 more
doaj   +1 more source

Second-generation tyrosine kinase inhibitors improve the survival of patients with chronic myeloid leukemia in whom imatinib therapy has failed

Haematologica, 2011
Background It has not been clearly established whether second-generation tyrosine kinase inhibitors actually improve the survival of patients with chronic myeloid leukemia in chronic phase who are given nilotinib or dasatinib therapy after treatment ...
Amr R. Ibrahim, Richard E. Clark, Tessa L. Holyoake, Jenny Byrne, Pat Shepherd, Jane F. Apperley, Dragana Milojkovic, Richard Szydlo, John Goldman, David Marin   +9 more
doaj   +1 more source

A ROR1 small molecule inhibitor (KAN0441571C) induced significant apoptosis of ibrutinib‐resistant ROR1+ CLL cells

eJHaem, 2021
ROR1 – a receptor tyrosine kinase – is overexpressed in CLL. Ibrutinib, a Bruton's tyrosine kinase inhibitor, is clinically effective in CLL but patients may develop resistance. We evaluated the effect of an ROR1 inhibitor, KAN0441571C, in CLL cells from
Amineh Ghaderi, Mohammad‐Ali Okhovat, Layung Sekar Sih Wikanthi, Ann Svensson, Marzia Palma, Johan Schultz, Thomas Olin, Anders Österborg, Håkan Mellstedt, Mohammad Hojjat‐Farsangi   +9 more
doaj   +1 more source

BCR-ABL1 tyrosine kinase sustained MECOM expression in chronic myeloid leukaemia [PDF]

, 2012
MECOM oncogene expression correlates with chronic myeloid leukaemia (CML) progression. Here we show that the knockdown of MECOM (E) and MECOM (ME) isoforms reduces cell division at low cell density, inhibits colony-forming cells by 34% and moderately ...
Jørgensen, Heather G., Holyoake, T.L., Holyoake, T., Abed El Baky, Mohamed, Bartholomew, C., Melo, Junia V., Roy, P., Melo, J.V., Abed El Baky, M., Roy, S., Jørgensen, H., Jorgensen, H.G., Strathdee, G., Strathdee, Gordon, Melo, J., Roy, Swagata, Holyoake, Tessa L., Roy, Poornima, Bartholomew, Christopher   +18 more
core   +1 more source